• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dabigatran Decreases Risk of Recurrent Venous Thromboembolism

Article

New findings from two double-blind, randomized trials, RE-MEDYSM and RE-SONATE®, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE). The results were published today in the New England Journal of Medicine.

VTE is the third most common cardiovascular disorder after heart disease and stroke, and consists of two related conditions caused by blood clots: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is when a blood clot develops in the deep veins of the leg or pelvis. The clot, or part of it, can break off from the site where it formed and travel through the veins (embolism). A PE can occur if the clot lodges in the arteries of the lungs.

Read the full story: http://bit.ly/13jM0zR

Source: News-Medical.Net

Related Videos
Ciara Zachary, PhD, MPH
Eleanor Perfetto, PhD
William Schpero, PhD, MPhil, MPH
Oncology experts at PCOC
Susan Cantrell, CEO of AMCP
Susan Cantrell, CEO of AMCP
Kelley L. Julian, PharmD, BCOP
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.